Use of Insulin Glargine to Treat Diabetic Ketoacidosis

• Status: Completed
• Trial end date: 2012-09-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine the effects of the addition of insulin glargine during the early phase of moderate to severe Diabetic Ketoacidosis (DKA) in children.

The investigators hypothesize that the addition of insulin glargine during the early phase of management of DKA will accelerate acidosis correction, decrease the length of insulin infusion, and decrease the total intensive care unit time in children admitted to the ICU.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Vanderbilt University Medical Center
• Treatments: Insulin Glargine

Criteria

Inclusion Criteria:

• Ages 6-18 y.o. presenting to Vanderbilt Children's Hospital (VCH) Emergency Room with:

• Established history of insulin dependent diabetes

AND:

• Chief c/o hyperglycemia or vomiting

• Venous pH < 7.24

• Serum Bicarbonate < 18

• Blood glucose > 150

• Urinary Ketones

Exclusion Criteria:

• Age < 6y.o.

• New onset diabetes

• Received IV insulin bolus prior to arrival to VCH Emergency Room (ER)

• Venous pH > 7.24

• Serum Bicarbonate > 18

• Pregnancy

• Received glargine within 12 hours prior to arrival to VCH Emergency Room/Pediatric Critical Care Unit